The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Body Composition
Body Water
/ metabolism
Electric Impedance
Extracellular Space
/ metabolism
Humans
Lung Neoplasms
/ drug therapy
Middle Aged
Retrospective Studies
Survival Rate
Water
/ metabolism
ECW/TBW
Lung cancer
bioelectrical impedance analysis
prognostic factor
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
19
04
2020
revised:
23
04
2020
accepted:
26
05
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
6
8
2020
Statut:
ppublish
Résumé
Extracellular water-to-total body water ratio (ECW/TBW) measured by bioelectrical impedance analysis (BIA) reportedly predicts clinical outcomes of various diseases. The aim of this retrospective study was to examine the association between ECW/TBW and therapeutic durability of chemotherapy and/or immune checkpoint inhibitors in advanced lung cancer. Patients with advanced lung cancer underwent BIA before chemotherapy and/or treatment with immune checkpoint inhibitors at our hospital between June 2018 and November 2019. Of 75 patients, 18 with ECW/TBW ≥0.4 were assigned to the overhydrated group (OH-G) and 57 patients ECW/TBW <0.4 were assigned to the non-overhydrated group (NOH-G). The median time-to-treatment failure was significantly shorter in the OH-G than in the NOH-G (p=0.003). Multivariate analysis revealed that ECW/TBW ≥0.4 predicted treatment failure [hazard ratio (HR)=2.508, 95% confidence interval (CI)=1.19-5.27; p=0.01]. The ECW/TBW may be an objective parameter for predicting therapeutic durability in advanced lung cancer.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Extracellular water-to-total body water ratio (ECW/TBW) measured by bioelectrical impedance analysis (BIA) reportedly predicts clinical outcomes of various diseases. The aim of this retrospective study was to examine the association between ECW/TBW and therapeutic durability of chemotherapy and/or immune checkpoint inhibitors in advanced lung cancer.
PATIENTS AND METHODS
METHODS
Patients with advanced lung cancer underwent BIA before chemotherapy and/or treatment with immune checkpoint inhibitors at our hospital between June 2018 and November 2019.
RESULTS
RESULTS
Of 75 patients, 18 with ECW/TBW ≥0.4 were assigned to the overhydrated group (OH-G) and 57 patients ECW/TBW <0.4 were assigned to the non-overhydrated group (NOH-G). The median time-to-treatment failure was significantly shorter in the OH-G than in the NOH-G (p=0.003). Multivariate analysis revealed that ECW/TBW ≥0.4 predicted treatment failure [hazard ratio (HR)=2.508, 95% confidence interval (CI)=1.19-5.27; p=0.01].
CONCLUSION
CONCLUSIONS
The ECW/TBW may be an objective parameter for predicting therapeutic durability in advanced lung cancer.
Identifiants
pubmed: 32620634
pii: 40/7/3931
doi: 10.21873/anticanres.14384
doi:
Substances chimiques
Antineoplastic Agents
0
Antineoplastic Agents, Immunological
0
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3931-3937Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.